Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Synthetic 20 amino acid peptide from 3rd extracellular domain of human CYSLTR1 / CYSLT1. Percent identity with other species by BLAST analysis: Human, Gorilla, Gibbon, Monkey (100%); Rabbit, Guinea pig (85%); Bovine, Elephant, Horse, Pig (80%).
LS-E28235 - Liquid - 50 µg 1 mg/ml - $145.00
Immunizing peptide used to generate LS-A1317. Useful for pre-absorption and neutralization of the antibody's antigen binding site.
Human CYSLTR1 / CYSLT1. BLAST analysis of the peptide immunogen showed no homology with other human proteins, except NMU (45%).
PBS, 0.1% Sodium Azide
Aliquot and store undiluted at -20°C or below for up to 1 year. Can be stored undiluted at 4°C for up to 1 month. Avoid freeze-thaw cycles.
Cysteinyl leukotriene receptor 1, a Chemoattractant Receptor, is detected in spleen, peripheral blood leukocytes, and lung smooth muscle (Lynch et al., 1999). It binds cysteinyl leukotrienes, which are neutrophil chemoattractants with potent proinflammatory action. Leukotrienes mediate many features of bronchial asthma such as edema, bronchial constriction, and hyperreactivity ( Bisgaard et al., 2000). Selective CysLT1 antagonists are used to treat asthma.